Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises YrkesAkademin in connection with its acquisition of Arcus
Mandate

Vinge advises YrkesAkademin in connection with its acquisition of Arcus

November 25, 2021 Employment and Benefits Corporate Crime & Compliance IT, Telecommunications and Outsourcing Real Estate and Construction Public Procurement M&A

Vinge has advised YA Holding AB (publ) ("YrkesAkademin") in connection with its acquisition of Arcus Utbildning & Jobbförmedling AB ("Arcus"). The acquisition is, inter alia, dependent upon securing the requisite financing.

Arcus was founded in 1998 and is the market leading company in matching services, i.e. to guide jobseekers into suitable employment or education, on behalf of the Swedish Employment Service. As per 30 June 2021, Arcus’ turnover was SEK 282 million for the past 12 months (LTM). At present, Arcus employs approximately 300 people.  

Vinge’s team consisted of Jonas Johansson together with Elsie Nassar and Amanda Steen (M&A), Mia Falk and Per Kjellstrand (Compliance), Ebba Svenburg (Employment Law), Elisabet Hallberg (Contracts), Karl-Hugo Engdahl (IT & GDPR), Ulf Pyk (Real Estate Law), Kristoffer Sällfors (Public Procurement) and Ellinor Gyllenhammar (VDR assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025